Abstract
To compare the efficacy, safety, and rate of response of intravenous iron sucrose and intramuscular iron sorbitol therapy for anemia during pregnancy. 100 antenatal cases of gestational age 14-32weeks were included in this prospective study. Cases were randomly divided into two groups. Group A, having 50 cases received intravenous iron sucrose, and 50 cases in Group B received intramuscular iron sorbitol. Response to therapy in both groups was studied and compared. The mean pretherapy hemoglobin in group A was 6.49gm/dl and in group B was 6.48gm/dl. The rise in hemoglobin after 4weeks of starting therapy was 3.52gm/dl in group A and 2.33gm/dl in group B. The difference was statistically significant (P<0.01). The mean time taken to achieve target hemoglobin (≥11gm/dl) was 6.37weeks in group A and 9.04weeks in group B. In group A, 8% (four) cases had grade I adverse effects. In group B, 24% (12) cases had grade I adverse effects. The difference was statistically significant (P=0.027). In both the groups, no case discontinued the therapy. Intravenous iron sucrose is safe, convenient, more effective, and faster acting therapy than intramuscular iron sorbitol therapy for treating moderate to severe anemia during pregnancy.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
